Standout Papers
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (2014)
- 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial (2010)
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial (2021)
Immediate Impact
6 by Nobel laureates 11 from Science/Nature 70 standout
Citing Papers
Renal cell carcinoma
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Works of Michael R. Harrison being referenced
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
2022
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Michael R. Harrison | 2875 | 1771 | 1648 | 174 | 6.0k | |
| Mark W. Onaitis | 4831 | 1947 | 2426 | 137 | 7.7k | |
| G. Petur Nielsen | 5029 | 2751 | 2081 | 218 | 10.0k | |
| Hidetaka Yamamoto | 2584 | 2020 | 1597 | 333 | 6.7k | |
| Sarah Dry | 2248 | 2319 | 1008 | 191 | 6.9k | |
| Edward J. Beattie | 3424 | 1824 | 2420 | 165 | 6.8k | |
| Penella J. Woll | 2956 | 4879 | 822 | 166 | 7.7k | |
| Jeffrey L. Port | 4099 | 1843 | 2246 | 158 | 6.6k | |
| Anthony L. Asher | 3557 | 2214 | 2266 | 198 | 8.2k | |
| William F. Sindelar | 4191 | 3343 | 2106 | 127 | 6.3k | |
| Rosalba Miceli | 5207 | 4358 | 2528 | 248 | 10.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...